Roivant highlighted a major cash realization from the global patent dispute involving Moderna, with Genevant Sciences and Arbutus Biopharma receiving an initial $950 million payment in July 2026 under their $2.25 billion patent infringement settlement.
Another $1.3 billion remains contingent on a resolution of Moderna’s Section 1498 appeal that is favorable to Genevant and Arbutus. The initial payment represents roughly 42% of the total potential settlement value.
The patent enforcement strategy is also expanding beyond Moderna. In July, Genevant and Arbutus filed three new international lawsuits against Pfizer and BioNTech, including one in Canada and two before the Unified Patent Court. The actions seek relief across 20 European countries and Canada, representing 21 jurisdictions in total. Discovery in the separate U.S. Pfizer/BioNTech case remains underway.
Roivant had $3.9 billion of consolidated cash, cash equivalents, restricted cash and marketable securities as of June 30, before including the $950 million Moderna payment received the following month. The company said its liquidity supports a cash runway into profitability.
The company also repurchased 7.3 million common shares for approximately $208.7 million during the quarter.
At the same time, Roivant continues advancing its clinical pipeline. Brepocitinib commercial preparations for dermatomyositis remain on track for a potential launch by the end of September 2026, while topline results from Phase 3 non-infectious uveitis and other clinical programs are expected through the second half of 2026.
Roivant’s cutaneous sarcoidosis program has also moved into Phase 3. In the earlier Phase 2 study, 77% of patients receiving brepocitinib 45mg achieved at least a 50% reduction in the study’s disease activity score compared with 0% of placebo patients.
KEY QUOTES:
“Our teams are deep in preparation for the potential launch of brepocitinib in dermatomyositis, we have enrolled the first patients in a new Phase 3 trial in cutaneous sarcoidosis, and we expect topline readouts from our NIU, PH-ILD and CLE studies before year end.”
“We remain focused on delivering for patients across each of these programs, and if we are successful across even some of these endeavors, we will look radically different on the other side.”
Matt Gline, CEO of Roivant
